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Abstract 
Background: New directly acting antiviral (DAA) therapy for hepatitis C (HCV) offers 
the potential for high cure rates in many patient groups previously considered 
difficult-to-treat, including those HIV/HCV co-infected. The high price of these 
medications is likely to limit access to treatment, at least in the short term. Early 
treatment priority is likely to be given to those with advanced disease but a more 
detailed understanding of the potential benefits in treating those with mild disease is 
needed. 
Objective: We hypothesised that successful HCV treatment within a co-infected 
population with mild liver disease would lead to a reduction in the use and costs of 
healthcare services in the 5 years following treatment completion. 
Methods:  We performed a retrospective cohort study of HIV/HCV co-infected 
patients without evidence of fibrosis/ cirrhosis who received a course of HCV therapy 
between 2004 and 2013. Detailed analysis of healthcare utilisation up to 5 years 
following treatment for each patient using clinical and electronic records was used to 
estimate healthcare costs. 
Results: Sixty-three patients were investigated, of whom 48/63 (76.2%) achieved 
sustained virological response 12 weeks following completion of therapy (SVR12). 
Individuals achieving SVR12 incurred lower health utilisation costs (£5,000 per-
patient) compared to (£10,775 per-patient) non-SVR patients in the five years after 
treatment. 
Conclusion: Healthcare utilisation rates and costs in the immediate 5 years following 
treatment were significantly higher in co-infected patients with mild disease that failed 
to achieve SVR12. This data suggests additional value to achieving cure beyond the 
prevention of complications of disease.  
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Introduction 
 
Hepatitis C (HCV) is estimated to have infected over 170 million people worldwide, 
accounting for 3% of the global population [1]. Co-infection with HIV and HCV is 
common due to shared routes of transmission with the prevalence of co-infection 
ranging from 9-30% in different settings [2-5]. Since the introduction of highly active 
antiretroviral therapies (HAART) and the reduction in mortality from malignancy and 
opportunistic infection, hepatic disorders have become a leading cause of death for 
HIV patients in developed nations [6-8], with HCV playing a major role. HIV infected 
individuals with HCV experience more rapidly progressive fibrosis and an increased 
risk of cirrhosis and hepatocellular carcinoma, occurring in 25% and 1.6% of co-
infected individuals over their lifetime, respectively [9, 10].  
New directly acting antivirals (DAAs) against HCV have the potential to cure many 
HCV/HIV co-infected patients who have not tolerated or have failed previous 
treatments. However, widespread access to these treatments is currently beyond 
existing health budgets [11] in most economies and their initial use is likely to be 
limited to patients with significant fibrosis or cirrhosis [12]. Strong justification of the 
cost-benefit of treatment in patients with mild disease will be required.   
Several studies have reported higher usage of healthcare services such as 
hospitalisations and emergency room visits in co-infected individuals than amongst 
HIV infected patients [13-16].  There is some evidence that SVR in HCV 
monoinfected patients is cost saving [17]. In contrast to HCV monoinfected patients, 
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HIV/HCV co-infected patients remain in secondary care even when cured and impact 
on healthcare utilisation has not been studied in this population. 
We aimed to investigate whether HIV/HCV co-infected patients who were 
successfully treated for mild hepatitis C had reduced usage of healthcare services 
and costs after completion of successful treatment.  
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Materials and Methods 
 
Study population 
Patients were eligible if they attended the study clinic between 1st January 2004 and 
1st March 2013. Patients included for analysis required (i) Confirmed positive HIV 
antibody status (ii) Evidence of HCV infection, HCV patients for this study were 
identified by a positive HCV RNA on more than one occasion and (iii) To have 
received and completed at least 3 months of treatment for HCV between 1st January 
2004 and 1st March 2013. This would allow us to obtain at least one year of follow-up 
for all patients by the date of data collection, 1st March 2014. Patients were included 
regardless of treatment type which included pegylated interferon (PEG-IFN, both α-
2b, Schering-Plough or α-2a, Roche), ribavirin (RBV) and latterly protease inhibitors 
(PI). Analysis was limited to patients without evidence of significant fibrosis to avoid 
confounding by the fact that patients with more advanced disease have greater 
healthcare costs, and that those with most advanced disease respond less well to 
therapy [18-20]. Patients we considered not to have significant fibrosis were those 
that had a fibroscan result <9.6kPa and/or a biopsy with ISHAK stage score <2/6 in 
the 2 years prior to treatment. Individuals that were currently on treatment were 
excluded from the study. Treated patients were separated into two groups based on 
outcome – those that attained SVR and those that did not (non-SVR) as shown in 
Figure 1. Patients were recruited from a single centre where the majority of patients 
are from West London, United Kingdom (UK).  
Data on patient characteristics, clinical data and healthcare utilisation were collected 
from clinical records supplemented by electronic records for investigations and 
hospital attendance. Data collected independently by UK collaborative HIV cohort 
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(UKCHIC) [21] was used to cross-reference information from hospital databases and 
verify patient selection. UKCHIC is a collaboration that routinely collects data on HIV 
positive individuals who have received care at any one of the associated centres in 
the UK.    
 
Baseline characteristics  
Baseline patient information for the entire HIV/HCV co-infected cohort included the 
patient’s age, gender, race, fibrosis/cirrhosis status, baseline laboratory data 
comprising of CD4 count, HCV genotype, HCV and HIV viral loads, fibroscan results 
and biopsies. Baseline analysis was then repeated for SVR and non-SVR groups to 
allow comparison between cohorts once individuals were identified. For both groups, 
additional information on treatments given and the precise dates of treatment 
completion were obtained from patient records.    
 
Healthcare utilisation 
Patients with mild liver disease who received a course of PEG-IFN and RBV +/- 
protease inhibitors in line with the British HIV Association (BHIVA) guidelines were 
considered for medical service utilisation analysis [22]. Forty-eight patients we 
identified achieving SVR and fifteen non-SVR patients were included. For each 
patient, annual resource utilisation data was recorded for up to 5 years post 
treatment with year 1 starting 12 weeks following treatment cessation. Healthcare 
follow-up was conducted up until 1st March 2014. Outpatient attendances, clinic 
visits, hospital admissions, nights spent at hospital, A&E visits, number of bloods 
taken, HCV viral loads, number of USS and fibroscans were recorded. Clinic visits 
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were denoted as consultant led encounters at the HIV study clinic. Outpatient 
attendances included both planned and unplanned visits to hospital outside of regular 
HIV clinic sessions. In the UK, a stable HIV patient routinely receives a follow up 
every 3-6 months as mentioned in the BHIVA monitoring guidelines and will have a 
regular blood test at least a week prior to each clinic visit. Individuals that are not 
tolerating treatment or with additional complications will need more frequent visits 
[23]. This study did not consider pharmacy costs of HIV and other drugs received 
during the follow up period, which were assumed to be the same in both SVR and 
non-SVR groups.  
  
Statistical analysis and costs 
We assessed differences in healthcare utilisation by comparison of rates per patient 
year of follow-up of each healthcare service. We followed this by calculating total 
utilisation rates over the 5 years and compared total usage per patient year between 
SVR and non-SVR groups. Risk ratios were then determined for non-SVR vs. SVR 
patients. Statistical significance was determined at p<0.05 estimated using two sided 
student t-tests. To fully assess the benefits of attaining an SVR we used mean costs 
as the factor of comparison. Healthcare service costs were obtained from the 
Department of Health using most recent reference costs, 2012-2013 [24]. Unit costs 
were found to be: Outpatient attendance including both visit and average cost of 
outpatient procedure £240; Consultant led HIV clinic visit £354; Hospital admission 
£693; Night stays £1489 per night; A&E visit £115; Bloods £27; HCV viral load £75; 
Diagnostic tests (fibroscans and ultrasound scans) each at £92. Total National Health 
Service (NHS) expenditure for SVR and non-SVR patients during the 5-year follow 
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up period were calculated using single unit costs and utilisation rates which were 
later compared.   
Results 
SVR vs. non-SVR characteristics 
A total of 63 co-infected patients with mild liver disease received and completed at 
least 3 months of antiviral therapy between January 2004 and March 2013. Table 1 
shows the comparison of baseline characteristics for SVR and non-SVR groups. 
Overall, 48/63 patients (76%) had successful treatment of which 28 patients (58%) 
had acute infection. Both SVR and non-SVR groups comprised predominantly of 
males. The distribution of age varied between groups where the majority (30/48, 
62.5%) of SVR patients were aged 45 or older, whereas (13/15) 86.6% of non-SVR 
patients were 44 or lower. A higher proportion of genotype 1 patients (44/139, 32%) 
received treatment as opposed to only 25% (2/8) of genotype 2 and 22% (7/32) of 
genotype 3 patients (data not shown). Twenty-five percent (11/44) of patients treated 
for genotype 1 and (4/10) 40% of patients treated for genotype 4 failed therapy whilst 
all individuals treated for genotypes 2 and 3 had successful outcomes.  
 
Health service utilisation post treatment 
Table 2 shows the annual healthcare utilisation rates per patient for each of the 
services measured post treatment. The median duration of follow-up was 4 years and 
5 years for SVR and non-SVR groups, respectively. Compared to those with a SVR, 
non-SVR patients had higher annual utilisation rates for five of the nine measured 
healthcare services (hospital admissions, fibroscans, USS, clinic visits and outpatient 
attendances) in the 5 years following treatment. A&E and night stays did not show 
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significant difference between both cohorts, this is due to the relatively low utilisation 
rates seen during each year of the follow up.   
 
We then investigated how the use of these services varied between groups over the 
follow up period. Figure 2 shows the utilisation rates per person year over the initial 5 
years upon treatment completion. Outpatient attendances were significantly higher in 
non-SVR patients (3.3 visits per patient year) when compared to 1.5 for SVR patients 
(p=0.0022). Likewise, significant differences were seen in the average number of 
clinic visits over the course of the study with SVR and non-SVR using the service 1.1 
and 2 times per patient year, respectively (p=0.0018). Those not achieving SVR were 
more likely to have an ultrasound scan and a fibroscan in the initial 5 years following 
treatment with a RR of 14.93 (95% CI, 4.95-45.04, p<0.0001) and 10.40 (95% CI, 
3.99-27.14, p<0.0001) respectively. There was an associated increase in relative risk 
with the use of all listed healthcare services in the absence of SVR, however results 
for hospital admissions and A&E visits did not prove statistically significant.   
 
Resource costs post treatment  
To ascertain the financial benefits of attaining a SVR we calculated total costs for 
resource utilisation. Table 3 shows the estimated costs per service over the 5 year 
follow up for both cohorts. Patients that failed treatment incurred higher healthcare 
utilisation costs than those successfully treated and this trend is apparent in all 
measured services. Healthcare costs for non-SVR subjects totalled £2,155 per 
patient year compared to only £1,000 for SVR patients. Over a 5-year period, 
utilisation costs would therefore amount to £10,775 and £5,000 for non-SVR and 
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SVR patients respectively. As very few A&E visits were observed throughout the 
study for both groups, the economic impact on reducing admissions is small. The 
greatest disparities in costs between the cohorts were found in ultrasounds 
amounting to a 93% difference between groups.  
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Discussion 
 
The study found that within a HIV/HCV co-infected population with mild disease, 
unsuccessful treatment is associated with significantly higher costs (£1,155 more per year) 
of healthcare utilisation per patient following HCV therapy than those who were 
successfully treated. Outpatient and clinic attendances were higher in non-SVR patients 
when compared to those achieving SVR (£766/£1000, 77%) in comparison to non-SVR 
group (£1,489/£2,155, 69%). A greater proportion of costs were attributable to hospital 
admission in those that failed treatment. Of the minority of patients that failed treatment, 
none had developed severe fibrosis or cirrhosis throughout the duration of the study and 
so healthcare analysis was not influenced by progression of disease. No significant 
difference was seen in the number of bloods taken between both cohorts reflecting the fact 
that both cohorts would continue to be monitored for their HIV irrespective of treatment 
response. It is also worth noting that although the total cost spent on inpatient services 
(hospital admissions and night stays) were higher for non-SVR patients (£471 per patient) 
than SVR patients (£91 per patient), the rates for inpatient services were very low for both 
groups (Table 2). 
This study adds to the growing literature on the consequences of successful treatment of 
HCV, which inform our understanding of cost-effectiveness. This is the first study to 
explore the impact of successful treatment in individuals with HIV co-infection and mild 
disease, an important group who may play a key role in on-going transmission of infection 
if not being prioritised for treatment based on liver fibrosis.  Recent work has explored the 
benefits of treatment in HCV monoinfected patients [17, 25], a different cohort from the 
one investigated here not least because HCV mono-infected individuals with mild disease 
can potentially be discharged from secondary care after successful treatment. A UK study 
reported a thirteen-fold difference in costs between SVR and non-SVR patients with 
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chronic hepatitis C limited to those with genotype 1 [17]. The healthcare services 
measured in the study were similar to those in our analysis with the addition of CT and 
MRI scans in place of fibroscans. Total costs incurred for SVR patients per year amounted 
to £54 in comparison to £506 for those who failed treatment [17]. A US study calculated 
post treatment healthcare costs in monoinfected HCV patients to be 1.6 times higher in 
non-SVR subjects than those with successful outcomes upon treatment [25]. That study 
considered those with cirrhosis grouped alongside patients with little or no liver disease 
and are thus not directly comparable to our findings.  
The study has several limitations. Outpatient attendances, hospital admissions and A&E 
visits were recorded based on all causes, we did not attempt to differentiate whether 
utilisation was due to liver related events caused by HCV.  Co-morbidities such as obesity 
and diabetes were not studied in detail and some change in use of services may reflect 
non-hepatic consequences of infection. The design of this study was intended to minimise 
the potential for confounding in findings as a result of the lower SVR rates seen in those 
with progressive fibrosis [20]. However, we cannot exclude the fact that there may be 
patients within the study where the extent of liver disease may be underestimated by 
previous fibroscans and biopsies. Whilst the largest study of this population to date, the 
numbers of patients included are relatively small and the findings require confirmation in 
other studies. In particular, data from a larger number of centres would be helpful to 
establish if the data are representative of wider practice (for example, the number of visits 
even in those patients achieving SVR is greater than would be expected under national 
guidelines).  The SVR rates seen in this study are relatively high (76%) and this likely 
reflects a significant number of patients receiving treatment for acute infection. Although 
different from the HCV mono-infection period, this is quite typical of practice in co-infection.  
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Finally, the study relied on data from electronic databases and patient records, and it may 
be that all patient related data was not captured (for example, attendances at other 
centres or in primary care). It is not possible to estimate the extent of this issue within this 
study though it may lead to an underestimate of the changes in health utilisation. In 
addition, this study did not consider pharmacy costs of HIV and other drugs received 
during the follow up period, which too will have contributed to the overall healthcare costs 
for both cohorts.  
The results from our study add to existing data informing the cost-effectiveness of antiviral 
therapies. Whilst we cannot yet know whether successful DAA therapy will have the same 
benefits, it is likely that the benefits will be similar but further, ideally larger, studies are 
required. It is possible that the difference between SVR and non-SVR groups will change 
with a longer period of follow-up, but it is likely that there will be greater divergence as 
disease progression in the non-SVR group will require more frequent monitoring. 
Conclusion 
 
This study was the first to compare the impact of successful HCV treatment on healthcare 
utilisation in a HIV/HCV co-infected population with mild disease. Our results show 
significant differences in healthcare costs and utilisation rates between individuals that are 
successfully treated for HCV compared to those failing treatment, despite the fact that they 
remain in secondary care.  
The study provides data in addition to the known benefits of SVR in reducing the risk of 
cirrhosis, hepatocellular cancer, end stage liver disease and disease transmission [26] and 
adds to the evidence for cost-effectiveness of treatment in this population.  
 
 
   Padam    Page 14 of 21 
 
 
 
 
 
Acknowledgements 
There was no specific funding for this study. GC is funded in part by the BRC of Imperial 
College NHS Trust and the MRC stratified Medicine Consortium (STOP-HCV). ET is 
funded by the Wellcome Trust and the MRC. The study was conceived by GC and JM. 
Data collection and analysis was performed by PP, SC, JM and GC. First draft was written 
by PP and GC. All authors were involved in drafting the manuscript.  
References 
1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 
17:107-115. [PubMed: 21091831] 
2. Sulkowski M, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J 
Viral Hepat. 2007; 14:371-386. 
3. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among 
patients infected with human immunodeficiency virus: a cross-sectional analysis of 
the US adult AIDS Clinical Trials Group. CID. 2002;34:831-7. 
4. National Aids Trust. Hepatitis C and HIV co-infection. 2012; 1-17  
5. Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, et al. The prevalence of 
hepatitis C virus (HCV) infection in HIV-positive individuals in the UK – trends in HCV 
testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat. 2010; 
17:569-77 [PubMed: 19840365] 
6. Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S et al. Is there evidence 
for an increase in the death rate from liver-related disease in patients with HIV? 
AIDS. 2005. 19:2117-25 
7. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing 
mortality due to end-stage liver disease in patients with human immunodeficiency 
virus infection. Clin Infect Dis. 2001; 32: 492– 497. [PubMed: 11170959] 
   Padam    Page 15 of 21 
 
 
 
 
 
8. Chen J, Feeney E, Chung R. HCV and HIV co-infection: mechanisms and 
management. Nat Rev Gastroenterol Hepatol. 2014; 1-10. [PubMed: 24535328] 
9. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) 
for hepatitis C. J Clin Pharmacol. 2004; 44:20–9. [PubMed: 14681338] 
10. Operskalski E, Kovacs A. HIV/HCV Co-infection: Pathogenesis, Clinical 
Complications, Treatment, and New Therapeutic Technologies. Curr HIV/AIDS rep. 
2011; 8:12-22. [PubMed: 21221855] 
11. Cooke G, Hill A. Hepatitis C can be cured globally, but at what cost? Science. 2014; 
345:141-142 [PubMed: 25013048]  
12. National Health Service. Clinical Commissioning Policy Statement: Sofosbuvir + 
Daclatasvir/Ledipasvir +/- Ribivirin for defined patients with Hepatitis C. 2014; 1-8. 
13. Grant W, Jhaveri RR, McHutchinson JG, Schulman K, Kauf T. Trends in Health Care 
Resource Use for Hepatitis C Virus Infection in the United States. Hepatology. 2005; 
42:1406-1413. [PubMed: 16317670] 
14. Linas B, Wang B, Smurzynski M, Losina E, Bosch R, Schackman B, et al. The impact 
of HIV/HCV co-infection on health care utilization and disability: results of the ACTG 
Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat. 2011; 18:506-
512. [PubMed: 20546501] 
15. Norton B, Park L, McGrath L, Proeschold Bell R, Muir A, Naggie S. Health Care 
Utilization in HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus 
Coinfection. AIDS Patient Care and STDS. 2012; 26:541-545. [PubMed: 22860997] 
16. Johnson T, Toliver J, Mao L, Oramasionwu C. Differences in outpatient care and 
treatment utilization for patients with HIV/HCV coinfection, HIV, and HCV 
monoinfection, a cross-sectional study. BMC Infect Dis. 2014; 14:1-10. [PubMed: 
24755037] 
   Padam    Page 16 of 21 
 
 
 
 
 
17. Backx M, Lewszuk A, White J, Cole J, Sreedharan A, van Sanden S, et al. The cost 
of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1–
infected patients who do or do not achieve sustained virological response to therapy. 
J Viral Hepat. 2014; 21:208-215. 
18. Gordon S, Hamzeh F, Pockros P, Hoop R, Buikema A, Korner E, et al. Hepatitis C 
virus therapy is associated with lower health care costs not only in noncirrhotic 
patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther. 
2013; 38:784-793. [PubMed: 23981040] 
19. Shiffman M, Benhamou Y. Patients with HCV and F1 and F2 fibrosis stage: treat now 
or wait? Liver Int. 2013; 1:105-110. [PubMed: 23286853] 
20. Ridruejo E. Predictors of Response to Chronic Hepatitis C Treatment. Future 
Virology. 2012; 7:1089-1101. 
21. UKCHIC. The UK Collaborative HIV Cohort Study. 2014.  
22. BHIVA. British HIV Association guidelines for the management of hepatitis viruses in 
adults infected with HIV 2013. HIV medicine. 2013; 14:1-71. 
23. Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A et al. British HIV 
Association guidelines for the routine investigation and monitoring of adult HIV-1 
infected individuals 2011. HIV Medicine 2012; 13:1-44  
24. Department of Health. Reference Costs 2012-2013. 2013; 1-57. 
25. Manos M, Darbinian J, Rubin J, Ray G, Shvachko V, Denis B et al. The Effect of 
Hepatitis C Treatment Response on Medical Costs: A Longitudinal Analysis in an 
Integrated Care Setting. J Manag Care Pharm. 2013; 9:438-447. [PubMed: 
23806057] 
26. Hill A, Saleem J, Simmons B, Cooke G. Effects of Sustained Virological Response on 
the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-
   Padam    Page 17 of 21 
 
 
 
 
 
analysis of 129 studies in 34,563 patients with Hepatitis C infection. 65th Annual 
Meeting of the American Association for the Study of Liver Diseases (AASLD 2014). 
Boston, November 7-11, 2014. Abstract 44.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Padam    Page 18 of 21 
 
 
 
 
 
 
Table 1. Baseline characteristics of SVR vs. non-SVR cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
Genotype for which treatment given 
b
as of March 1st 2014 
HCV = hepatitis C virus; HIV = human immunodeficiency virus; SVR = sustained virological response.   
 
 
 SVR n=48  Non-SVR n=15 
 n (%)  n (%) 
Gender  
Female  1 (2.1)  0  
Male 47 (97.9)  15 (100) 
Age (years) 
Mean, standard deviation 46, 8.23   41, 6.65  
Median, range (min, max) 46, 38 (29,67)   40, 28 (30,58)  
Distribution (years)  
25-34 3 (6.25)  2 (13.3) 
35-44 15 (31.3)  11 (73.3) 
45-54 24 (50)  1 (6.7) 
55-64 5 (10.4)  1 (6.7) 
>65 1 (2.1)  0  
Race/Ethnicity       
White  40 (83.3)  13 (86.7) 
Black  2 (4.2)  0  
Asian 5 (10.4)  1 (6.7) 
Other 1 (2.1)  1 (6.7) 
HCV Status      
Acute 28 (58.3)  8 (53.3) 
Chronic 20 (41.7)  7 (46.7) 
HCV genotypea      
Genotype 1 33 (68.8)  11 (73.3) 
Genotype 2 2 (4.2)  0  
Genotype 3 7 (14.6)  0  
Genotype 4 6 (12.5)  4 (26.7) 
HIV viral loadb  (copies/ml)       
<50 36 (75)  13 (86.7) 
≥50 12 (25)  2 (13.3) 
CD4 countb (copies/μl)      
101-500 19 (39.6)  3 (20) 
501-1000 27 (56.3)  11 (73.3) 
>1000 2 (4.2)  1 (6.7) 
Median duration of follow 
up  (years) 
4   5  
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Table 2. Annual post treatment healthcare utilisation of SVR vs. non-SVR patients  
 
a
Beginning 12 weeks from treatment completion (SVR12)  
Rates for each year given per patient.  
HCV = hepatitis C virus; SVR = sustained virological response; USS = ultrasound scans
 Years after treatment  
      Year 1a  Year 2  Year 3  Year 4  Year 5 
Healthcare service  SVR non-SVR  SVR non-SVR  SVR non-SVR  SVR non-SVR  SVR non-SVR 
Outpatients attendances 1.81 4.20  1.77 3.07  1.3 3.29  1.23 2.31  1.3 2.44 
Clinic visits 1.4 2.40  1.2 1.93  0.95 2.00  0.97 1.46  0.85 2.11 
Hospital admissions 0.04 0.13  0.07 0.29  0.08 0.50  0.03 0.38  0 1 
Nights stayed in hospital 0.02 0  0.02 0.21  0.05 0.29  0.1 0  0 0.11 
A&E 0 0.7  0.07 0.07  0.08 0.07  0 0  0 0 
Blood draws 2.48 2.93  2.2 2.21  1.9 2.43  1.6 1.54  1.65 2.11 
HCV viral loads 1.19 1.47  1.09 0.86  0.98 1.07  0.67 0.54  0.45 0.56 
USS 0 0.2  0.05 0.5  0 0.43  0 0.23  0.05 0.33 
Fibroscans 0 0.2  0 0.29  0 0.36  0.1 0.31  0.05 0.33 
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Table 3. Healthcare costs per patient per year for SVR vs. non-SVR cohorts  
  HIV/HCV  
 Follow-up 
(years) 
Outpatient 
attendances 
Clinic 
visits 
Hospital 
admissions 
Night 
stays 
A&E visits Bloods HCV viral 
loads 
USS Fibroscans Total Cost per patient 
per year 
SVR (n=48) 182 £67200 £72216 £6237 £10423 £690 £10071 £12975 £276 £2024 £182112 £1000 
Non-SVR 
(n=15) 
65 £51120 £45666 £18711 £11912 £345 £3996 £4575 £2024 £1748 £140097 £2155 
 
Unit costs obtained from the Department of Health. Costs displayed in GBP 
HCV = hepatitis C virus; USS = ultrasound scans; SVR = sustained virological response  
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Figure Legends 
 
Figure 1. 
a
As of March 1st 2014 
HCV = hepatitis C virus; HIV = human immunodeficiency virus; SVR = sustained virological response.   
 
Figure 2. 
Total follow up years: 182 SVR, 65 non-SVR 
Statistical significance detected at p<0.05 
HCV = hepatitis C virus; SVR = sustained virological response; USS = ultrasound scan; A&E = accident and emergency; 
 
 
